| NCT#: & Link | NCT03151629 |
| NCT QR Code |  |
| Available as of: | July 15, 2024 |
| Contract: | Caris |
| Indication Category: | Prostate |
| Study Sponsor: | PCCTC |
| Protocol #: | PRODIGY |
| Title: | International Registry for Men With Advanced Prostate Cancer (IRONMAN) (IRONMAN) |
| Highlight Details: | IRONMAN Registry Sub-Study: PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations |
| Biomarkers: | HRR mutations (BARD1, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L) |
| Indication: | Prostate (mCRPC) |
| Phase: | |
| Treatment Line: | |
| Study Drug/Test Compound: | |
| Notes | |
| Recruitment Status: | Just In Time |
| Participating Institution: | Salinas Valley Health |
| Salinas Valley Health Clinical Research Program: | Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, research@salinasvalleyhealth.com |
(Tumor Board) & Other Clinical Trials at Salinas Valley Health
